ZANTAC INJECTION PREMIXED(Ranitidine)
Generic Name and Formulations:
Ranitidine (as HCl) 1mg/mL in sodium chloride 0.45%; IV infusion; preservative-free.
Company:
Teligent, Inc.

Select therapeutic use: Hyperacidity, GERD, and ulcers
Indications for ZANTAC INJECTION PREMIXED:
Hospitalized patients with pathological hypersecretory conditions, intractable duodenal ulcer. Short-term alternative to oral therapy.

Adult:
For slow IV drip only. >16yrs: Intermittent infusion: 50mg every 6–8hrs (infuse over 15–20min); usual max 400mg/day. Continuous IV infusion, or for Zollinger-Ellison: see literature. Renal impairment (CrCl<50mL/min): 50mg every 18–24hrs or more often if needed (intermittent only). Coincide a dose for end of hemodialysis.

Children:
<1month: not recommended. ≥1month–16yrs: Treatment of duodenal ulcer: 2–4mg/kg per day in divided doses every 6–8hrs; max 50mg every 6–8hrs.

Warnings/Precautions:
History of acute porphyria: not recommended. Renal impairment: reduce dose. Hepatic dysfunction. Discontinue if hepatic disorders occur. Monitor SGPT if on high-dose IV therapy for ≥5 days. Pregnancy (Cat.B). Nursing mothers.

Interactions:
May increase triazolam, midazolam, glipizide, procainamide levels. May decrease ketoconazole, atazanavir, delaviridine, gefitnib levels. Monitor anticoagulants. May cause false (+) urine protein test with Multistix.

See Also:
ZANTAC

ZANTAC EFFERDOSE

ZANTAC SYRUP

ZANTAC INJECTION

Pharmacological Class:
H2 blocker.

Adverse Reactions:
Headache, GI disturbances, jaundice, hepatitis, rash; rare: CNS disturbances, arrhythmias, blurred vision, arthralgia, myalgia, inj site reactions, blood dyscrasias, anaphylaxis, angioneurotic edema, acute interstitial nephritis, bradycardia with rapid administration (IV); increased risk of pneumonia (see literature).

How Supplied:
Tabs 150mg—60, 180, 500; 300mg—30; EFFERdose tabs—60; Syrup—pt; Inj single dose 2mL—10; Multidose 6mL—1; Premixed 50mL—24